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Prevention of age related macular degeneration
Current evidence suggests that vitamin E alone is unlikely to have a large
protective effect
Age related macular degeneration may be recog›nised in its early stages by the appearance ofdrusen and pigment change within the retina,
but it produces few symptoms. Progression of age
related macular degeneration can result in irreversible
visual loss and is the commonest cause of blindness in
the Western world. New treatments such as photo›
dynamic therapy and macular surgery may limit the
extent of visual loss and in a few cases even restore
sight.1 But in contrast with cataract surgery, outcomes
are unpredictable and the treatment is burdensome for
patients and carries massive resource implications for
healthcare providers. The prospect of prevention is
thus very appealing from the public health perspective,
not to mention that of the patient who may be at risk of
losing the ability to recognise faces, read a newspaper,
or to live independently. Increasing evidence suggests
that cumulative oxidative damage increases risk of age
related macular degeneration.2 But evidence from
trials and reviews suggests that the antioxidant vitamin
E, used alone, does not seem to have a protective effect
against age related macular degeneration.
The retina is particularly susceptible to oxidative
stress as its need for oxygen is large, it is exposed to
high levels of light, and its membranes are rich in read›
ily oxidised polyunsaturated fatty acids. Evidence from
in vitro and animal studies suggests that the
antioxidants vitamin E and vitamin C can protect the
retina against photochemical damage. Carotenoids
also have antioxidant properties and two of these,
lutein and zeaxanthin, make up the macular pigment
that is thought to limit retinal oxidative damage by fil›
tering out blue light. However, results of observational
studies linking intake or blood levels of antioxidants
with risk of age related macular degeneration have
been inconsistent.3–7 Over the past decade or so, several
randomised controlled trials have been set up to try to
resolve the uncertainty about the role of antioxidants.
In this issue Hugh Taylor and colleagues report the
findings of one such study (p 11).8 The vitamin E, cata›
ract and age›related macular degeneration study
(VECAT) was set up in Melbourne, Australia, in 1995.
One aim of the study was to determine whether
vitamin E supplementation (500 IU/day) would
influence the development and progression of age
related macular degeneration. Most of the 1193 study
participants had no or mild signs of age related macu›
lar degeneration at the start of the study. After four
years, there were no statistically significant differences
between the intervention and the placebo groups in
the primary outcome, incidence of early age related
macular degeneration, or in any of the secondary out›
comes, progression of early age related macular
degeneration, development of late age related macular
degeneration, changes in visual acuity, or changes in
visual function. Set against the results of a recent cross
sectional observational study that found statistically
significant inverse associations between plasma vita›
min E and both early and late age related macular
degeneration,7 these findings are disappointing.
One explanation, as Taylor et al point out, may be
that four years of supplementation is too short for any
protective effect to be detected. The lowered risk of age
related macular degeneration linked with high intakes
or blood levels of antioxidants in some observational
studies could reflect a lifelong pattern of eating.
Another possibility is that the baseline antioxidant sta›
tus of the trial participants was too high for
supplementation to be effective: plasma vitamin E lev›
els were near the top of the reference range for both
treatment groups, and over 25% of participants had
been taking supplementary vitamin E before the trial.
Thirdly, this trial was originally set up with the statisti›
cal power to detect a 15% reduction in cataract;
although, as the authors state, the sample size may have
been adequate to detect a 50% reduction in the
incidence of age related macular degeneration, it may
have been unrealistic to expect vitamin E to have such
a large effect. If they had wanted to have 80% power to
detect a 20% reduction in incidence, which seems a
more likely goal, they would have needed a sample size
over eight times larger than that available.
It may be, of course, that vitamin E has no role in
preventing age related macular degeneration. Results
from a Finnish trial showing that neither vitamin E nor
â carotene, nor a combination of these antioxidants,
had any effect on risk of age related macular degenera›
tion in 941 male smokers supports this view, though
this study too may have lacked statistical power.9 How›
ever, a trial from the United States with 3640
participants was able to show that vitamin E, in combi›
nation with vitamin C, â carotene and zinc, reduced
risk of progression to advanced age related macular
degeneration by 25% after six years in those already
showing evidence of disease.10 It was not possible to
examine the effect of vitamin E alone.
Two Cochrane reviews, which took account of the
preliminary report of this trial, conclude that there is
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currently no evidence from randomised trials that
healthy people should take antioxidant vitamin supple›
ments to prevent the onset of age related macular
degeneration.11 However, the authors suggest that on the
basis of the US trial an antioxidant and mineral supple›
ment containing vitamin E, vitamin C, â carotene, and
zinc may delay the progression of the disease in people
with moderate to severe age related macular degenera›
tion.12 On current evidence it is unlikely that vitamin E
alone has a large protective effect.
Nigel F Hall ophthalmologist
(crg@mrc.soton.ac.uk)
Catharine R Gale senior research fellow
MRC Environmental Epidemiology Unit, Southampton General
Hospital, Southampton, SO16 6YD
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Detaining dangerous people with mental disorders
New legal framework is open for consultation
The draft mental health bill published last weekintroduces a new legal framework for the com›pulsory treatment of people with mental dis›
orders in hospitals and in the community.1 On the day
it was unveiled the bill was condemned and labelled as
little more than a detention plan for dangerous mental
patients.2 The white paper on reforming the Mental
Health Act that preceded the draft bill attracted a great
deal of attention because of its over›riding emphasis
on public safety.3–5 The fact that it was not well received
is hardly surprising given that it was born from an
unpopular green paper and proposals for managing
dangerous people with severe personality disorder
described as glaringly wrong and unethical.6–10
Rather than continuing the theme of public
protection,3 the ministerial foreword accompanying
the draft bill seeks to reassure us that the new law will
promote patients’ rights and protect them.11 The term
“dangerous people with severe personality disorder”
used in the white paper does not receive a single men›
tion in the draft bill. This may offer some reassurance,
but it does not mean that dangerous people with per›
sonality disorders or any other forms of mental disor›
der are excluded—far from it.
The procedure for compulsion is very similar to
that described in the white paper. This involves a single
pathway with three distinct stages: a preliminary exam›
ination, a period of formal assessment lasting up to 28
days, and then treatment under a Mental Health Act
order. Four conditions must be satisfied before any
compulsory powers can be used: there must be a men›
tal disorder (as defined below); this must be of a nature
or degree warranting medical treatment; treatment
must be necessary for the health or safety of the patient
or the protection of others; and appropriate treatment
must be available for the disorder.
“Mental disorder” is defined as “any disability or
disorder of mind or brain which results in impairment
or disturbance of mental functioning.” In contrast to
the current act, there are no specific exclusion criteria.
The broad definition of mental disorder not only
means that dangerous people with severe personality
disorder are included, but it also raises the possibility of
compulsory treatment for sexual deviancy and
dependence on alcohol or drugs. The “treatability test,”
which has been used to exclude some patients with
psychopathic disorder and mental impairment from
treatment under the current act, is also conspicuous by
its absence. The draft bill does not go as far as the white
paper in advocating compulsory powers to manage
behaviours arising from the disorder, but a broad defi›
nition of “medical treatment” probably includes
treatments amounting to this.
For patients other than offenders, a new mental
health tribunal will authorise compulsory treatment
beyond 28 days. The bill clearly says that in the case of
orders authorising medical treatment in hospital, the
order must state whether hospital transfer and leave
may only be granted with the agreement of the
tribunal and whether the order may only be discharged
by the tribunal. Restricting the remit of the “clinical
supervisor” will impose restrictions on the patient.
The draft bill makes provision for treatment
without consent. The explanatory notes state that
although such treatment does breach the physical
integrity, the government’s view is that it can be
justified under the European Convention on Human
Rights Article 8(2) on the basis that the interference is
in accordance with the law, is proportionate, and is in
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